The antidiabetic activity of the new composition “Thigliben” on the experimental dexamethasone diabetes mellitus model in rats




diabetes mellitus type 2, experimental pharmacology, complex hypoglycemic drugs, glibenclamide


Being a metabolic disease with long-term hyperglycemia, diabetes mellitus significantly increases the risk of microvascular and macrovascular diseases and organ pathologies, respectively. The creation of the new composition “Thigliben”, which allows not only qualitatively controlling diabetic hyperglycemia, but also providing a preventive and/or therapeutic effect on the development of diabetic polyneuropathy was pathogenetically reasonable.

Aim. To study the antidiabetic activity of “Thigliben” on the experimental dexamethasone diabetes mellitus in rats.

Materials and methods. The pharmacological study of the antidiabetic activity of the new composition “Thigliben” in the dose of 4 mg/kg was performed. The experimental studies were conducted on a standard model of the experimental dexamethasone type 2 diabetes mellitus in rats. Glibenclamide in the dose of 0.6 mg/kg (corresponds to an average human daily dose of 10 mg) was selected as the reference drug.

Results. It was found that by its effects on the carbohydrate and lipid metabolism the new composition “Thigliben” was similar to the reference drug glibenclamide administered in a higher dose. By the antioxidant activity this composition exceeded the effect of the reference drug, provided that normalization of the TBA-RS level in the liver homogenate was significant. The new composition “Thigliben” normalized all the parameters of the cerebral energy metabolism studied relative to the control pathology group and its efficiency was significantly higher than that of the reference drug glibenclamide. The new composition “Thigliben” increased the content of ATP by 109 % compared to the control pathology group, in contrast to 68 % on the background of glibenclamide; restored the activity of citrate synthase by 65 %, succinate dehydrogenase by 134 %, and pyruvate dehydrogenase by 61 % relative to the control pathology group. For glibenclamide the change in these indicators was 28 %, 50 %, and 22 %, respectively. The results obtained suggest that the metabolic effect of “Thigliben” composition is significantly more effective than that of the reference drug glibenclamide.

Conclusions. The new composition “Thigliben” is a promising antidiabetic drug with a pronounced hypolipidemic, antioxidant effect and the ability to restore energy deficiency; it is its significant advantage over the standard treatment regimens, including the average therapeutic doses of glibenclamide.

Author Biographies

N. A. Tsubanova, National University of Pharmacy

Doctor of Pharmacy (Dr. habil.), professor of the Department of Clinical Pharmacology, Institute for Continuing Education
of Pharmacy Professionals

O. H. Berdnyk, National University of Pharmacy

teaching assistant of the Department of Pharmacoeconomics


Meng, F., Sun, Y., Heng, B. H., & Leow, M. K. S. (2020). Analysis via Markov decision process to evaluate glycemic control strategies of a large retrospective cohort with type 2 diabetes: the ameliorate study. Acta Diabetologica.

Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., … Zimmerman, R. S. (2010). The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy: A retrospective analysis. Diabetes Care, 33(6), 1224–1229.

Achila, O. O., Ghebretinsae, M., Kidane, A., Simon, M., Makonen, S., & Rezene, Y. (2020). Factors Associated with Poor Glycemic and Lipid Levels in Ambulatory Diabetes Mellitus Type 2 Patients in Asmara, Eritrea: A Cross-Sectional Study. Journal of Diabetes Research, 2020, 1–12.

Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., … Holman, R. R. (2008). Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care, 31(5), 845–851.

Nasr, P., Fredrikson, M., Ekstedt, M., & Kechagias, S. (2020). The Amount of Liver Fat Predicts Mortality and Development of Type 2 Diabetes in Non‐alcoholic Fatty Liver Disease. Liver International.

6. Pat. 134591 Ukraine. № u 201812544. (2019). Farmatsevtychna kompozytsiya dlya likuvannya tsukrovoho diabetu 2 typu.

Stefanov, O. V. (Eds.) (2001). Doklinichni doslidzhennia likarskykh zasobiv. Kyiv: Avitsena.

Hrytsiuk, M. I., Boichuk, T. M., Petryshev, O. I. (2014). Svit medytsyny ta biolohii, 2(44), 199-203.

Rebrova, O. Yu. (2006). Statystycheskyi analyz medytsynskykh dannykh. Prymenenye paketa prykladnykh prohramm STATISTICA.Moscow: MedyaSfera, 312.

Buren, J., Ereksson, J. (1999). Dexamethasone decreases GLUT 1 and GLUT 4 content in primary cultured rat adipocytes. Diabetol, 42(1), 170-175.

Konrad, D., Somwar, R., Sweeney, G., Yaworsky, K., Hayashi, M., Ramlal, T., & Klip, A. (2001). The Antihyperglycemic Drug α-Lipoic Acid Stimulates Glucose Uptake via Both GLUT4 Translocation and GLUT4 Activation. Diabetes, 50(6), 1464–1471.

Mohamed, A. K., Bierhaus, A., Schiekofer, S., Tritschler, H., Ziegler, R., & Nawroth, P. P. (1999). The role of oxidative stress and NF-κB activation in late diabetic complications. BioFactors, 10(2-3), 157–167.






Pre-clinical studies of new drugs